[1] Giuliani E, As-Sanie S, Marsh EE.Epidemiology and management of uterine fibroids[J]. Int J Gynaecol Obstet, 2020, 149(1): 3-9. [2] 唐梅,洪峰,关菡,等. 贵州省30~79岁世居侗族妇女检出子宫肌瘤的人群特征[J]. 中华疾病控制杂志,2020,24(10):1170-1174,1201. [3] 周蓉. 子宫肌瘤对生育力的影响及其围手术期保护[J]. 实用妇产科杂志,2024,40(2):84-87. [4] Ahmad A, Kumar M, Bhoi NR, et al.Diagnosis and management of uterine fibroids: current trends and future strategies[J]. J Basic Clin Physiol Pharmacol, 2023, 34(3): 291-310. [5] Millien C, Katz AM, Mukherjee J, et al.Uterine fibroid: A socially malignant illness in Haiti[J]. Anthropol Med, 2022, 29(3): 255-270. [6] 子宫肌瘤的诊治中国专家共识专家组. 子宫肌瘤的诊治中国专家共识[J]. 中华妇产科杂志,2017,52(12):793-800. [7] 陈娟,宋化雨,程瑶瑶,等. 攀枝花市子宫肌瘤发病的影响因素研究[J]. 华南预防医学,2021,47(7):844-847. [8] 曾令雪,王秋霞,廖莉苹. 育龄期妇女子宫肌瘤患病影响因素及手术治疗方式的卫生经济学调查分析[J]. 中国社会医学杂志,2023,40(6):696-700. [9] 盖纳,朱丽艳,周琼,等. 子宫肌瘤患者剔除术后再发及影响因素研究[J]. 华南预防医学,2024,50(1):68-71. [10] 中华医学会健康管理学分会,中国营养学会,中国医疗保健国际交流促进会生殖医学分会,等. 超重或肥胖人群体重管理专家共识及团体标准[J]. 中华健康管理学杂志,2018,12(3):200-207. [11] 娄诤,李春明,周坚红. 子宫肌瘤病因与预防[J]. 实用妇产科杂志,2024,40(2):81-84. [12] 张敏,徐菲娜,蒋小明,等. 645例育龄期妇女孕前妇科疾病检出状况及影响因素的分析[J]. 中国妇幼健康研究,2020,31(10):1423-1428. [13] Lou Z, Huang Y, Li S, et al.Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990-2019: An age-period-cohort analysis for the global burden of disease 2019 study[J]. BMC Public Health, 2023, 23(1): 916. [14] 钱庆庆,范玲. 护士群体子宫肌瘤患病现状及影响因素分析[J]. 中国医科大学学报,2020,49(6):512-518. [15] Dolmans MM, Petraglia F, Catherino WH, et al.Pathogenesis of uterine fibroids: Current understanding and future directions[J]. Fertil Steril, 2024, 122(1): 6-11. [16] Yang Q, Ali M, Treviño LS, et al.Epigenetic modulation of inflammatory pathways in myometrial stem cells and risk of uterine fibroids[J]. Int J Mol Sci, 2023, 24(14): 11641. [17] 贺宇恒,谭容容,刘莉莉,等. 2 818例未产女性孕前体成分特点的现况分析[J]. 生殖医学杂志,2024,33(3):337-343. [18] Afrin S, El Sabah M, Manzoor A, et al.Adipocyte coculture induces a pro-inflammatory, fibrotic, angiogenic, and proliferative microenvironment in uterine leiomyoma cells[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(1): 166564. [19] Das P, Jungari S.Prevalence, risk factors and health-seeking behavior of menstrual disorders among women in India: A review of two-decade evidence[J]. Glob Health Action, 2024, 17(1): 2433331. [20] Keizer AL, Semmler A, Kok HS, et al.Modifiable prognostic factors in uterine fibroid development: A systematic review of literature[J]. J Obstet Gynaecol, 2024, 44(1): 2288225. [21] Song S, Park S, Song BM, et al.Risk of uterine leiomyomata with menstrual and reproductive factors in premenopausal women: Korea nurses' health study[J]. BMC Womens Health, 2023, 23(1): 305. [22] 郝子兰,马惠荣,林雄坡,等. 女性子宫肌瘤发病危险因素的Meta分析[J]. 中国性科学,2023,32(2):64-68. [23] Bhat AS, Singh NA, Rymbai E, et al.Importance of fibrosis in the pathogenesis of uterine leiomyoma and the promising anti-fibrotic effects of dipeptidyl peptidase-4 and fibroblast activation protein inhibitors in the treatment of uterine leiomyoma[J]. Reprod Sci, 2023, 30(5): 1383-1398. [24] Moore KR, Harmon QE, Zhao S, et al.Bacterial vaginosis and prospective ultrasound measures of uterine fibroid incidence and growth[J]. Epidemiology, 2022, 33(3): 415-421. [25] AlAshqar A, Lulseged B, Mason-Otey A, et al. Oxidative stress and antioxidants in uterine fibroids: Pathophysiology and clinical implications[J]. Antioxidants (Basel), 2023, 12(4): 807. |